By Brad Sorensen, CFA
OTC: IZOZF
READ THE FULL IZOZF RESEARCH REPORT
Izotropic (OTC: IZOZF) is an emerging medical device company aiming to transform breast imaging with its innovative IzoView Breast CT system. At its core, Izotropic’s mission is straightforward but ambitious: to make breast cancer detection faster, clearer, and more comfortable for patients—particularly for the large number of women whose dense breast tissue makes traditional mammograms less effective. The company holds exclusive global rights to its technology from the University of California, Davis, where the underlying breast CT platform was developed over many years of academic research. With that foundation, Izotropic is now working to bring this technology to market through a dedicated imaging system that could redefine how clinicians see and diagnose breast cancer.
Izotropic represents a rare opportunity in an area that combines cutting-edge imaging innovation with a substantial unmet clinical need. The global market for breast imaging is growing steadily, and nearly half of women fall into the “dense breast” category, a demographic that standard mammography often struggles to serve. IzoView directly targets this challenge by producing true three-dimensional CT images of the breast without the painful compression required by traditional scans. This technology offers clearer visualization of tissue structure and lesions, which can potentially improve both detection rates and diagnostic confidence.
As the company moves closer to commercialization and revenue recognition, being strategic with finances is important. The recent earnings report shows that management is taking that responsibility seriously—increasing cash balances, minimizing expenses, and narrowing the loss per share to a breakeven point. This solid balance sheet and financial management allow flexibility in pursuing business opportunities such as those described below.
As mentioned, company management recognizes that breast cancer and issues with standard breast imaging access and quality exist across the world and has recently announced an agreement to establish an entity known as Izotropic Africa with an entity referred to as “a business group (BG)”. According to the company, the new entity intends to license, market, distribute, and evaluate manufacturing and/or assembly of IzoView Breast CT and certain follow-on products in all of Africa and the Gulf Cooperation Council: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
This area has an urgent need for advanced breast cancer screening, with estimates suggesting over 200,000 cases of breast cancer annually and mortality rates exceeding 50% due to delayed diagnoses and the limited access to advanced care many of the citizens have. Additionally, the company reports that the addressable market for advanced imaging devices is expected to exceed $500 million by 2030.
The details of the agreement are that BG will hold a 60% interest and Izotropic will hold a 40% interest—subject to the final structure being agreed to by both parties by April 30, 2026. Other terms of the agreement indicated BG has committed to developing and executing an annual business plan focused on the sales, marketing, and distribution of IzoView and any follow-on products in Africa and the Gulf Cooperation Council. BG has also committed to securing a major hospital site in Morocco in Q1, 2026 for installation of an IzoView Breast CT Imaging System to serve as a research data collection and clinical study and approval location forming the foundation for regulatory engagement and market entry within the region, initiating approval processes with government health ministries in the designated territories, and assessing the feasibility of establishing manufacturing and/or assembly capabilities in Morocco to serve Africa and the Gulf area.
Lastly, the parties have agreed upon an estimated first-year start-up budget, pursuant to which Izotropic’s 40% share is estimated at USD $120K. Izotropic has agreed to advance 25% (USD $30K) for the first three-month period against its portion of those estimated costs. All financial contributions and operational commitments of Izotropic beyond the initial capital advance remain subject to execution of the formal agreement and securing of financing.
This entity in Africa is already showing progress in the region, with the company announcing that Izotropic Africa has entered into partnership discussions with the Mohammed VI Foundation for Science & Health (FM6SS). According to the company, the FM6SS operates as a public utility institution under the patronage of King Mohammed VI, supporting healthcare reform, research advancement, innovation, and institutional partnerships within Morocco. Management notes that as part of these discussions, an IzoView device valued at $500K would be placed at a leading hospital in Morocco at no cost as a clinical research site to support local clinical evaluation and regulatory approvals. The discussions also include the evaluation of opportunities for localized manufacturing and assembly initiatives in Morocco, with the kingdom’s geographic position at the intersection of Europe, Africa, and the Middle East providing access to regional markets with established logistics channels. This is another step in growing the scope of the IzoView technology and toward opening up vast new markets for the game-changing device.
For investors, Izotropic represents a higher-risk, high-potential opportunity that has a management that is clearly aggressively expanding its market opportunity. In our view, the company’s valuation remains modest relative to the scale of the problem it is addressing and the potential impact of its technology. We believe this agreement is another sign that IZOZF is poised to move higher as its superior technology begins to be distributed throughout the world—and investors with a higher risk tolerance should consider investing before the train leaves the station.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.